Tim Dyer has weathered many storms and has recently done it again. After Addex Therapeutics Ltd. reached critically low levels of cash in 2023, the company’s CEO found a way to generate the cash needed to feed the biotech he co-founded 22 years ago.
On 3 April 2024, the Swiss company announced a spin-out, Neurosterix, which it launched with the investment management firm Perceptive...